Retham Technologies
Diagnostics | Hemostasis and Thrombosis
Series Seed | Lead Investor
Milwaukee, Wisconsin
Retham is developing HITDx™, a functional immunoassay for heparin-induced thrombocytopenia (HIT), a life-threatening immune reaction to Heparin, one of the world’s most widely used anticoagulant medications. The diagnostic is based on a proprietary cryopreserved platelet technology and platform with potential to support additional platelet-based diagnostics, blood research and drug-development applications.